Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 1c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $3 million versus the consensus estimate of $3.82 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded